3 completed, 2 recruiting, 1 not yet recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Multiple Sclerosis, Primary Progressive: new trials by email Literature Review of Multiple Sclerosis, Primary Progressive trials Research Report on Multiple Sclerosis, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis Orca-Q, myeloablative regimen, Tacrolimus - Primary Progressive Multiple Sclerosis, Multiple Sclerosis | Phase 1 | Not yet recruiting | Orca Biosystems, Inc. | 10 | 2027-03-01 | 2026-11-13 |
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Contineum Therapeutics | 16 | 2024-12-09 | 2025-08-06 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Recruiting | Stanford University | 12 | 2024-04-10 | 2026-02-27 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 74 | 2023-08-01 | 2026-07-02 |
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 105 | 2017-12-01 | 2023-03-10 |
| Open-label Study of Liothyronine in MS liothyronine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 | Completed | Johns Hopkins University | 20 | 2015-07-01 | 2018-02-12 |
Multiple Sclerosis, Chronic Progressive (6) · Multiple Sclerosis (4) · Multiple Sclerosis, Relapsing-Remitting (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1) · Pathologic Processes (1) · Sclerosis (1)
Chronic Disease (6) · Disease Attributes (6) · Pathological Conditions, Signs and Symptoms (6) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Immune System Diseases (5) · Nervous System Diseases (5) · Pathologic Processes (5) · Autoimmune Diseases (4) · Multiple Sclerosis (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Inflammation (1) · Leukoencephalopathies (1)
Bendamustine Hydrochloride (1) · Busulfan (1) · Clemastine (1) · Insulin (1) · Sugars (1) · Tacrolimus (1) · Thiotepa (1) · Triiodothyronine (1) · fludarabine (1)
Johns Hopkins University (2) · Contineum Therapeutics (1) · Orca Biosystems, Inc. (1) · Stanford University (1) · University of California, San Francisco (1)
United States (4) · United Kingdom (1)
Scott Newsome, DO (2) · Ari J Green, MD, MCR (1) · Ellen Mowry, MD, MCR (1) · Jeffrey Dunn, MD (1) · Stephen Huhn, MD (1)